Long-term effects of irbesartan and atenolol on the renin-angiotensin-aldosterone system in human primary hypertension: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).
Article Details
- CitationCopy to clipboard
Malmqvist K, Ohman KP, Lind L, Nystrom F, Kahan T
Long-term effects of irbesartan and atenolol on the renin-angiotensin-aldosterone system in human primary hypertension: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).
J Cardiovasc Pharmacol. 2003 Dec;42(6):719-26.
- PubMed ID
- 14639093 [ View in PubMed]
- Abstract
We examined long-term influence of the angiotensin II type 1-receptor blocker irbesartan and the beta1-adrenergic receptor blocker atenolol on some neurohormonal systems implicated in the pathophysiology of cardiac hypertrophy. Thus, 115 hypertensive patients with left ventricular hypertrophy were randomized to receive double-blind irbesartan or atenolol, with additional therapy if needed. Neurohormone measurements and echocardiography were performed at weeks 0, 12, 24, and 48. Left ventricular mass was reduced more by irbesartan than by atenolol (-26 g/m2 versus -14 g/m2, P = 0.024), despite similar reductions in blood pressure. Plasma renin activity and angiotensin II increased (P < 0.001) by irbesartan (0.9 +/- 0.7 to 3.4 +/- 4.2 ng/mL x h, and 3.0 +/- 1.6 to 13.0 +/- 17.7 pmol/L), but decreased (P < 0.01) by atenolol (1.0 +/- 0.6 to 0.7 +/- 0.6 ng/mL x h, and 3.4 +/- 1.6 to 3.2 +/- 2.2 pmol/L). Serum aldosterone decreased (P < 0.05) by both irbesartan (346 +/- 140 to 325 +/- 87 pmol/L) and atenolol (315 +/- 115 to 283 +/- 77 pmol/L). Changes in left ventricular mass by irbesartan related inversely to changes in plasma renin activity, angiotensin II, and aldosterone (all P < 0.05). Plasma levels and 24-hour urinary excretions of catecholamines, plasma leptin, proinsulin, insulin and insulin sensitivity remained largely unchanged in both groups. Thus, the renin-angiotensin aldosterone system appears to be an important non-hemodynamic factor in the regulation of left ventricular mass.
DrugBank Data that Cites this Article
- Pharmaco-metabolomics
Drug Drug Groups Metabolite Change Description Atenolol Approved Aldosterone decreased Atenolol decreases the level of Aldosterone in the blood Irbesartan Approved Investigational Aldosterone decreased Irbesartan decreases the level of Aldosterone in the blood - Pharmaco-proteomics
Drug Drug Groups Gene Gene ID Change Interaction Chromosome Irbesartan Approved Investigational AGT 183 increased irbesartan results in increased expression of AGT protein 1q42.2 Irbesartan Approved Investigational AGT 183 increased irbesartan results in increased expression of AGT protein 1q42.2 Atenolol Approved AGT 183 decreased Atenolol results in decreased expression of AGT protein 1q42.2 Atenolol Approved REN 5972 decreased Atenolol results in decreased expression of REN protein 1q32.1 Irbesartan Approved Investigational REN 5972 increased irbesartan results in increased expression of REN protein 1q32.1